Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4Z15M)

• Drug Name: 8-Octyl-benzolactam-V9 Drug Info
• Synonyms: CHEMBL206866; 8-Octyl-benzolactam-V9; 8-Octylbenzolactam-V9

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11574614
  TTD Drug ID: DM4Z15M

Molecule-Related Drug Atlas

Drug(s) Targeting PKC-eta messenger RNA (PRKCH mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[2]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[3]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[4]
ISIS 6445	DMXJ4SO	Discovery agent	N.A.	Investigative	[5]
ISIS 6432	DMQHN43	Discovery agent	N.A.	Investigative	[5]
ISIS 6553	DM5L387	Discovery agent	N.A.	Investigative	[5]
ISIS 6581	DMEAVPQ	Discovery agent	N.A.	Investigative	[5]
ISIS 6442	DM7KSRG	Discovery agent	N.A.	Investigative	[5]
ISIS 6434	DMNVLE2	Discovery agent	N.A.	Investigative	[5]
ISIS 6431	DMEUCI2	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Protein kinase C gamma (PRKCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[6]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[2]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[7]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[8]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[9]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[10]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[11]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[11]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[11]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting PKC-delta messenger RNA (PRKCD mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[2]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[10]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[3]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[4]
Go 6983	DMKVTZN	Discovery agent	N.A.	Investigative	[12]
Diheptan-3-yl 5-(hydroxymethyl)isophthalate	DMBAY7P	Discovery agent	N.A.	Investigative	[13]
Dihexan-3-yl 5-(hydroxymethyl)isophthalate	DM8TBQ9	Discovery agent	N.A.	Investigative	[13]
ISIS 10310	DMT6H9S	Discovery agent	N.A.	Investigative	[5]
ISIS 17252	DMW40NK	Discovery agent	N.A.	Investigative	[14]
ISIS 10303	DM205TE	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting PKC-theta messenger RNA (PRKCQ mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[4]
ISIS 109351	DM508BS	Discovery agent	N.A.	Investigative	[15]
ISIS 109352	DMWK1XC	Discovery agent	N.A.	Investigative	[15]
ISIS 109353	DM6AJMC	Discovery agent	N.A.	Investigative	[15]
ISIS 109355	DMFIQGW	Discovery agent	N.A.	Investigative	[15]
4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile	DMB07TU	Discovery agent	N.A.	Investigative	[16]
4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile	DMH360U	Discovery agent	N.A.	Investigative	[16]
ISIS 109354	DM1REKQ	Discovery agent	N.A.	Investigative	[15]
4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile	DMAU0SF	Discovery agent	N.A.	Investigative	[16]
4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile	DMM8AY5	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting PKC-epsilon messenger RNA (PRKCE mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[2]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[17]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[10]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[4]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[18]
ISIS 7942	DMN0A1R	Discovery agent	N.A.	Investigative	[5]
ISIS 7948	DMYZE8R	Discovery agent	N.A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PKC-delta messenger RNA (PRKCD mRNA)	TT7A1BO	KPCD_HUMAN	Inhibitor	[1]
PKC-epsilon messenger RNA (PRKCE mRNA)	TT57MT2	KPCE_HUMAN	Inhibitor	[1]
PKC-eta messenger RNA (PRKCH mRNA)	TTONI0R	KPCL_HUMAN	Inhibitor	[1]
PKC-theta messenger RNA (PRKCQ mRNA)	TT1MS7X	KPCT_HUMAN	Inhibitor	[1]
Protein kinase C gamma (PRKCG)	TTRFOXJ	KPCG_HUMAN	Inhibitor	[1]

References

• [1] Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
• [2] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [3] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [4] A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
• [5] US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
• [6] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [7] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [8] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [9] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [10] Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
• [11] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [12] Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
• [13] Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
• [14] US patent application no. 6,235,723, Antisense oligonucleotide modulation of human protein kinase C-.delta. expression.
• [15] US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression.
• [16] First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32.
• [17] Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
• [18] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.